A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease
November 1, 2024
Most of us don’t have many autologous stem cell transplant (Auto-HSCT) patients whom we follow, but this topic seems ripe for an American Board of Internal Medicine (ABIM) question. Ruxolitinib seems quite effective for steroid refractory sclerotic chronic graft-versus-host disease (cGHVD).
